Innovative and adaptive strategies for new drug development are needed to maximize the potential of cell and gene therapies. CRA’s Lev Gerlovin with co-authors Walter Colasante and Pascale Diesel explain in this Cell and Gene article. Click here to read the article.
ASCO 2024 review: The benefits and barriers of biomarkers in oncology
Biomarkers: what do we mean? – The term “biomarkers” can be broadly clustered into four categories: molecular, histologic, radiographic and physiological. –...